Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:27 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2881–2904 of 26,684 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: Severe Sepsis With Septic Shock
Interventions: Interleukin-7, Placebo; Drug
Lead sponsor: Revimmune; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Bacterial Infections
Interventions: QPX7728, Placebo, QPX2014; Drug
Lead sponsor: Qpex Biopharma, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Cypress, California

Conditions: Parkinson Disease, Depression
Interventions: OnabotulinumtoxinA, Control; Biological
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 95 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hyperkalemia
Interventions: Sodium Zirconium Cyclosilicate (SZC), SZC Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 2,690 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 57
States / cities: Huntsville, Alabama • Mesa, Arizona • Bakersfield, California + 47 more

Conditions: Hypertension
Interventions: Vitamin D, calcitriol, Placebo; Drug
Lead sponsor: Atlanta VA Medical Center; Federal
Eligibility: 18 Years to 80 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: Gastrointestinal Neoplasm
Interventions: Endoscopic Submucosal Dissection, Novel Rigidizing Overtube; Procedure · Device
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 22 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Mucus Obstruction, Intubation
Interventions: mucomyst, sodium chloride (saline); Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Speech and Language Disorder, Cerebral Palsy, Hemiplegia, Hemiparesis
Interventions: Speech-language therapy (SLT), Modified constraint-induced movement therapy (mCIMT); Behavioral
Lead sponsor: Shirley Ryan AbilityLab; Other
Eligibility: 15 Months to 7 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Uncomplicated Symptomatic Urinary Tract Infections
Interventions: Limosilactobacillus reuteri 3613, Placebo; Dietary Supplement
Lead sponsor: Church & Dwight Company, Inc.; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Infertility
Interventions: Progesterone-IBSA Injectable Solution, Progesterone Vaginal Gel with Applicator, Placebo Vaginal gel with applicator, Placebo injectable solution; Drug
Lead sponsor: IBSA Institut Biochimique SA; Industry
Eligibility: 35 Years to 42 Years · Female only
Enrollment: 688 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 24
States / cities: Tempe, Arizona • Encino, California • Los Angeles, California + 20 more

Conditions: Lumbar Degenerative Disc Disease
Interventions: SB-01 For Injection, Sham Needle; Drug
Lead sponsor: Spine BioPharma, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 417 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 30
States / cities: Birmingham, Alabama • Phoenix, Arizona • Napa, California + 24 more

Conditions: Brain Death, Organ Donors, Lung Transplantation
Interventions: Naloxone, Normal saline; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 13 Years to 70 Years
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 4
States / cities: Denver, Colorado • Metairie, Louisiana • St Louis, Missouri + 1 more

Conditions: Arthritis, Osteoarthritis, Osteoarthritis, Hip
Interventions: tanezumab, Placebo; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 627 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 99
States / cities: Mobile, Alabama • Paradise Valley, Arizona • Peoria, Arizona + 74 more

Conditions: Alzheimer's Disease
Interventions: ACC-001 3 μg/ QS-21 50 μg, ACC-001 10 μg/ QS-21 50 μg, Placebo- Phosphate buffered saline (PBS); Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years to 80 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 40
States / cities: Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 17 more

Conditions: Chronic Heart Failure (CHF)
Interventions: RLX030, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Age-Related Macular Degeneration
Interventions: E10030, bevacizumab or aflibercept, E10030 sham injection; Drug
Lead sponsor: Ophthotech Corporation; Industry
Eligibility: 50 Years and older
Enrollment: 645 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 100
States / cities: Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 88 more

Conditions: Post-Traumatic Stress Disorder
Interventions: orvepitant, Placebo; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 26
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Beverly Hills, California + 23 more

Conditions: Muscle Cramp
Interventions: L-Carnitine, Placebo; Dietary Supplement
Lead sponsor: University of Southern California; Other
Eligibility: 16 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 3
States / cities: Los Angeles, California

Conditions: Respiratory Syncytial Virus (RSV)
Interventions: Investigational RSV vaccine MV-012-968 (Dosage 1), Investigational RSV vaccine MV-012-968 (Dosage 2), Investigational RSV vaccine MV-012-968 (Dosage 3; single-dose), Investigational RSV vaccine MV-012-968 (Dosage 3; two-dose), Placebo (single-dose), Placebo (two-dose); Biological · Other
Lead sponsor: Meissa Vaccines, Inc.; Industry
Eligibility: 6 Months to 36 Months
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 12
States / cities: Phoenix, Arizona • La Mesa, California • Atlanta, Georgia + 9 more

Conditions: Dravet Syndrome
Interventions: Fenfluramine treatment (Fintepla), Hypercapnia Challenge using the device (RespirAct); Drug · Device
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 16 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Excessive Sleepiness, Shift-work Disorder
Interventions: Solriamfetol 150 mg, Solriamfetol 300 mg, Placebo; Drug
Lead sponsor: Axsome Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 44
States / cities: Auburn, Alabama • Cullman, Alabama • Chandler, Arizona + 37 more

Conditions: Chronic Bronchitis, Chronic Obstructive Pulmonary Disease
Interventions: Erdosteine; Drug
Lead sponsor: Adams Respiratory Therapeutics; Industry
Eligibility: 40 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: King of Prussia, Pennsylvania

Conditions: Multiple Sclerosis
Interventions: 4-session Relaxation Training, 4-session Behavioral Activation, 4-session Cognitive Therapy; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Bronchial Asthma, Status Asthmaticus
Interventions: Standard of Care therapies, NiPPV Therapy, Routine Respiratory Care; Procedure · Device
Lead sponsor: Arkansas Children's Hospital Research Institute; Other
Eligibility: 2 Years to 17 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Little Rock, Arkansas

Search by objective public record fields.

A Study of IL-7 to Restore Absolute Lymphocyte Counts in Sepsis Patients

P1 Single and Multiple Ascending Dose (SAD/MAD) Study of IV QPX7728 Alone and Combined With QPX2014 in NHV

Trial of OnabotulinumtoxinA for Depression in Parkinson Disease

Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes)

Vitamin D and Blood Pressure

Novel Rigidizing Overtube in Colonic Endoscopic Submucosal Dissection

Comparison of Different Mucoactive Agents for the Care of the Intubated Patient in a Surgical Trauma Intensive Care Unit

Effect of mCIMT Casting on Speech-language Outcomes in Children With Hemiparesis

Assess the Effects of a Limosilactobacillus Supplement on Recurrence of UTI in Healthy Women During a 6-month Period

Subcutaneous Progesterone in Frozen- Thawed Single Euploid Blastocyst Transfer.

Moderate - Severe Degenerative Disc Disease Evaluation of the Lumbar Spine

Naloxone for Optimizing Hypoxemia Of Lung Donors

Tanezumab in Osteoarthritis Of The Hip

Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease

Renal Hemodynamic Effects of RLX030A in Subjects With Chronic Heart Failure (CHF)

A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy

Orvepitant (GW823296) in Adult Post Traumatic Stress Disorder

Oral Carnitine for Cramps in Pregnancy

Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seronegative Children 6-36 Months

The FINTEPLA as an Anti-SUDEP Therapy in Dravet Syndrome Project

Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)

Phase 2 Study - Erdosteine in Patients With CB/COPD

Factorial Optimization Trial to Test Cognitive Behavioral Therapy Components for Multiple Sclerosis Fatigue

NiPPV in the Treatment of Acute Asthma Exacerbations